Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

IDS LIMITED

Immunodiagnostic Systems Holdings PLC (IDS) develops, manufactures, and markets immunoassays and automated immunoanal... read more Featured Products: More products

Download Mobile App




FDA-Cleared Assay Enables Comprehensive Automated Testosterone Testing

By LabMedica International staff writers
Posted on 13 May 2026

Accurate evaluation of androgen status often requires concordant measurement of total testosterone, free testosterone, and sex hormone‑binding globulin. More...

Reference methods such as equilibrium dialysis with liquid chromatography/mass spectrometry can be operationally complex, rely on calculations, and present reproducibility challenges. A newly cleared assay now adds total testosterone to a platform that already measures free testosterone and sex hormone‑binding globulin, enabling a single‑platform workflow.

Revvity, through its subsidiary Immunodiagnostic Systems (IDS), received U.S. Food and Drug Administration (FDA) clearance on May 13, 2026, for the Total Testosterone automated chemiluminescence immunoassay (ChLIA). Together with the company’s FDA‑cleared ChLIA tests for free testosterone and sex hormone‑binding globulin (SHBG), the addition delivers the only FDA‑cleared ChLIA testosterone testing portfolio with direct measurement of all three analytes. The combined menu is positioned to support comprehensive assessment of testosterone‑related disorders on a single platform.

The portfolio enables direct ChLIA measurement of total testosterone, SHBG, and free testosterone, providing first‑ and second‑line diagnostic testing capabilities for suspected hypogonadism in men. All assays run on IDS random‑access automation platforms, allowing laboratories to consolidate testing without batching constraints. By replacing equilibrium dialysis–liquid chromatography/mass spectrometry (ED‑LC/MS) methods that require complex technologies and calculations and can present operational and reproducibility challenges, the workflow is significantly streamlined without compromising accuracy and reliability.

The clearance also expands Revvity’s broader endocrinology offering. Additional FDA‑cleared assays in the company’s reproductive endocrine disorders portfolio include 17‑OH progesterone (17‑OHP), androstenedione, and prolactin. Together, these tests are designed to simplify clinical workflows on a single automated platform.

“Adding the total testosterone assay to our automated ChLIA platform transforms the offering to a wholly integrated solution that supports diagnostic testing for androgen‑related conditions in both men and women,” said Arvind Kothandaraman, vice president and general manager, Euroimmun North America. “This clearance demonstrates our commitment to continued expansion of our portfolio to aid in the timely diagnosis of endocrine disorders.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Slide Scanner System
NanoZoomer S540MD
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.